MetLife Investment Management’s Ventyx Biosciences VTYX Stock Holding History

MetLife Investment Management’s Portfolio VTYX Stock Details VTYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-26,731	Closed	-$58.5K	–	2827
2024 Q4	$58.5K	Buy	26,731 +11,543	+76%	+$26.2K	﹤0.01%	2727
2024 Q3	$33.1K	Sell	15,188 -18,207	-55%	-$41.9K	﹤0.01%	2796
2024 Q2	$77.1K	Buy	33,395 +8,339	+33%	+$34.6K	﹤0.01%	2690
2024 Q1	$138K	Buy	+25,056	New	+$115K	﹤0.01%	2382
2023 Q4	–	Sell	-24,841	Closed	-$863K	–	2866
2023 Q3	$863K	Hold	24,841	–	–	0.01%	1312
2023 Q2	$815K	Buy	24,841 +11,815	+91%	+$407K	0.01%	1385
2023 Q1	$436K	Hold	13,026	–	–	﹤0.01%	1725
2022 Q4	$427K	Hold	13,026	–	–	﹤0.01%	1741
2022 Q3	$455K	Hold	13,026	–	–	﹤0.01%	1707
2022 Q2	$159K	Buy	+13,026	New	+$195K	﹤0.01%	2456

Other funds holding VTYX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MetLife Investment Management's VTYX Position: Q1 2025 in Review

MetLife Investment Management sold out of Ventyx Biosciences (VTYX) in Q1 2025, closing a stake of 26,731 shares — an estimated $58.5K sold.

MetLife Investment Management first reported a position in VTYX in Q2 2022 and held it in 10 quarters. The position peaked at $863K in Q3 2023. 116 funds tracked by Wall St. Rank hold VTYX as of Q1 2025.

MetLife Investment Management reported no remaining Ventyx Biosciences position as of Q1 2025 after selling out during the quarter.
MetLife Investment Management sold 26,731 Ventyx Biosciences shares in Q1 2025, an estimated $58.5K.
MetLife Investment Management first reported a position in Ventyx Biosciences in Q2 2022 and held it in 10 quarters.
MetLife Investment Management's Ventyx Biosciences position peaked at $863K in Q3 2023.
116 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2025.

Based on MetLife Investment Management's 13F filing for Q1 2025, filed 14 May 2025.